Eli Lilly and Company is in advanced negotiations to acquire Kelonia Therapeutics for a sum exceeding $2 billion, according to sources familiar with the matter on April 19, 2026. The proposed transaction represents a significant expansion of Lilly’s oncology division, specifically targeting next-generation treatments for multiple myeloma. The deal would integrate Kelonia’s proprietary in vivo gene delivery technology into Lilly’s internal research and development pipeline, moving the pharmaceutical giant further into the genetic medicine space.
Kelonia Therapeutics, based in Boston, is recognized for its in vivo lentiviral vector (iVEC) platform. Unlike traditional CAR-T cell therapies, which require the extraction, modification, and re-infusion of a patient’s cells—a process that is both time-consuming and costly—Kelonia’s technology is designed to deliver genetic payloads directly to target cells within the patient’s body. This approach has the potential to simplify the administration of cell therapies and increase patient access to treatments. The lead candidate in Kelonia’s pipeline is a next-generation therapy for multiple myeloma, a bone marrow cancer that remains a high priority for global pharmaceutical firms.
The acquisition talks follow a successful multi-year collaboration between the two companies. In early 2024, Eli Lilly, through its oncology unit Loxo@Lilly, entered into a research and development agreement with Kelonia. That initial deal provided Kelonia with an upfront payment and potential milestone payments totaling nearly $800 million. The transition from a partnership to a full acquisition suggests that early-stage data from the collaboration met or exceeded Lilly’s internal benchmarks for efficacy and safety.
Under the leadership of Chief Scientific Officer Daniel Skovronsky, Eli Lilly has pursued acquisitions to diversify its revenue streams beyond its dominant positions in diabetes and obesity care. The integration of Kelonia would provide Lilly with a foundational platform in genetic medicine that could be applied to therapeutic areas beyond oncology, including immunology and neurology. Neither Eli Lilly nor Kelonia Therapeutics has issued an official statement regarding the specific terms or the timeline for the deal’s completion, though an announcement is expected by the end of the current fiscal quarter.
The $2 billion valuation reflects a premium on Kelonia’s intellectual property and its manufacturing capabilities. As part of the deal, Lilly is expected to retain Kelonia’s specialized research team and its laboratory facilities in Massachusetts. This move aligns with Lilly’s broader strategy to compete with other major players in the cell and gene therapy market, such as Bristol Myers Squibb and Johnson & Johnson, who have already established significant footprints in the multiple myeloma space.